Pluri (NASDAQ:PLUR) Shares to Reverse Split on Monday, April 1st

Pluri Inc. (NASDAQ:PLUR) shares are going to reverse split on the morning of Monday, April 1st. The 1-8 reverse split was announced on Monday, April 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 1st.

Pluri Trading Down 13.7 %

Shares of Pluri stock opened at $0.88 on Thursday. Pluri has a 12-month low of $0.43 and a 12-month high of $1.07. The company has a market cap of $36.49 million, a price-to-earnings ratio of -1.52 and a beta of 1.45. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 3.69. The company’s 50-day moving average price is $0.81 and its 200-day moving average price is $0.65.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings data on Monday, February 12th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.11 million during the quarter. Pluri had a negative return on equity of 177.94% and a negative net margin of 6,708.40%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of Pluri during the third quarter valued at approximately $28,000. Citadel Advisors LLC boosted its stake in shares of Pluri by 128.1% during the fourth quarter. Citadel Advisors LLC now owns 57,481 shares of the company’s stock valued at $33,000 after purchasing an additional 32,279 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Pluri during the third quarter valued at approximately $81,000. Finally, Values First Advisors Inc. boosted its stake in shares of Pluri by 168.4% during the third quarter. Values First Advisors Inc. now owns 135,547 shares of the company’s stock valued at $81,000 after purchasing an additional 85,037 shares during the period. 16.59% of the stock is currently owned by institutional investors.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.